First Time in Human Study Using GSK2330672

Completed · Phase 1 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.

Key facts

Study ID

NCT01416324

Run by

GlaxoSmithKline

People needed

17

Starts

2011-06-15

Expected to finish

2011-09-09

Last updated by the study team

2017-06-20

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• healthy volunteer
• 18-60 yrs of age
• for subjects age 50 and above: negative fecal occult blood test within 3 months prior to expected start of dosing, and normal results from sigmoidoscopy or colonoscopy within 5 yrs prior to dosing.
• if female, must be of non-childbearing potential

You may not qualify if…

• pregnant or breastfeeding females
• positive HIV
• positive Hep B, or Hep C within 3 months of screening
• positive drugs of abuse screening
• triglycerides > 250 mg/dL
• current or chronic history of liver disease
• any gastrointestinal or gastrointestinal related conditions that could affect fat or bile acid reabsorption
• pancreatitis
• colon cancer or 1st degree relative who has had colon cancer
• abnormal lung function tests
• inability to perform lung function tests
• unwilling to abstain from smoking, alcohol, caffeine, illicit drugs as directed by the site staff
• exposure to more than 4 new chemical entities in the 12 months prior to the first dosing day.
• where participation in the study would results in donation of more than approximately 550mL of blood in a 56-day period.

Where it is running

• GSK Investigational Site — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.